Drugs / [18F]NOS
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05885594 | Aug 2023 → Mar 2027 expected | alcohol-related disorders | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04401917 | Dec 2020 → Dec 2026 expected | HIV infectious disease, substance-related disorder | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04062526 | Aug 2019 → Apr 2027 expected | Parkinson disease | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01407796 | Dec 2010 → Apr 2012 | pneumonia | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (18)F-NOS | “We developed a novel tracer for PET that binds to iNOS in vivo, (18)F-NOS.” PMID 25525182 ↗ Dec 2014 |
| Known as | \[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine | “\[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical” NCT05885594 ↗ |
| Modality | Diagnostic / imaging agent | “We developed a novel tracer for PET that binds to iNOS in vivo, (18)F-NOS.” PMID 25525182 ↗ Dec 2014 |